Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy
International Archives of Allergy and Immunology · 2023
DOI: 10.1159/000531332 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2023. Verfasst von Alexandra Chabot und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Bee Venoms, Cost Savings, Hypersensitivity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
IgE-mediated bee venom allergy can be treated with allergen-specific immunotherapy (AIT). Subcutaneous immunotherapy (SCIT) is time and cost intensive due to the repeated consultations, but the costs are justified by the high risk of potentially life-threatening allergic reactions, including anaphylaxis. However, intralymphatic immunotherapy (ILIT) offers potential to reduce treatment costs due to a significant reduction in injections and a shorter duration of therapy. Therefore, we calculated the cost savings that arise when switching from SCIT to ILIT.
Methods
Treatment protocols for ILIT were based on previous ILIT studies. Treatment protocols for SCIT were based on routine treatment at the University Hospital Zurich (USZ). The treatment costs were calculated based on the internal hospital information system (KISIM).
Results
The calculations revealed a potential two-fold reduction in treatment costs if ILIT is used instead of SCIT in patients with bee venom allergy. The costs could be reduced from EUR 11,612.59 with SCIT to EUR 5,942.15 with ILIT over 5 years.
Conclusions
This study shows that bee venom ILIT has a cost-benefit potential for health insurances and patients, which should encourage further ILIT studies and which should be taken into account when considering future implementation of ILIT in the standard care of venom allergy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Zurich, Zurich, Switzerland.
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Zitieren
APA
Chabot, A., Lang, C., Kündig, T. M., Schmid-Grendelmeier, P., & Johansen, P. (2023). Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy. International Archives of Allergy and Immunology. https://doi.org/10.1159/000531332
Vancouver
Chabot A, Lang C, Kündig TM, Schmid-Grendelmeier P, Johansen P. Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy. International Archives of Allergy and Immunology. 2023. doi:10.1159/000531332
BibTeX
@article{Chabot2023,
author = {Chabot, Alexandra and Lang, Claudia and Kündig, Thomas M and Schmid-Grendelmeier, Peter and Johansen, Pål},
title = {Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy},
journal = {International Archives of Allergy and Immunology},
year = {2023},
doi = {10.1159/000531332}
}
EUVIMED